NR3C2 and chronic kidney disease: Concordantly, the Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure (ARTS-HF) was designed to compare the efficacy and safety of finerenone with eplerenone in patients with type 2 DM and/or CKD suffering from chronic HF with a reduced ejection fraction and already treated with evidence-based therapy for HF for at least three months [77].